Online inquiry

IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11347MR)

This product GTTS-WQ11347MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Neuromyelitis optica (NMO) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ11347MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8967MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ILV-094
GTTS-WQ2620MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 557
GTTS-WQ12034MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MM-302
GTTS-WQ6268MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ9553MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA J6M0
GTTS-WQ11767MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MK-1308
GTTS-WQ12777MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ7571MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW